Leerink Notes Positive Read Through for Juno Therapeutics (JUNO) from Iterim ZUMA-1 Data (KITE)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Stocks hit by tech slide; yen flails at intervention zone
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen hits fresh 34-year lows against dollar ahead of BOJ meeting
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
BTIG Says Kite Pharma's (KITE) ZUMA-1 Data Doesn't Alter Broader Picture; Affirms at 'Neutral'
September 27, 2016 12:13 PM EDTBTIG affirmed its Neutral rating on Kite Pharma (Nasdaq: KITE) amid ZUMA-1 study results released Monday night.
Analyst Dane Leone commented, We think that the 3-month Complete Response rate of ~33% for the DLBCL cohort is within the 30 40% range expected by investors,... More
Juno Therapeutics (JUNO) Gains on Kite Pharma News
September 26, 2016 4:05 PM EDTJuno Therapeutics (NASDAQ: JUNO) gains after-hours following positive trial news from rival Kite Pharma, Inc., (Nasdaq: KITE). Shares are up 8.6%.
Kite... More
